Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response

Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Sever M, Klicek R, et al. · Inflammopharmacology

Records the peptide as 'safe in clinical trials for inflammatory bowel disease (PL 10, PLD 116, PLD 14736, Pliva, Croatia)'; in the accompanying rat work, gastric vessels stayed visible and gastric, oesophageal and duodenal lesions were inhibited after alcohol instillation, where the three standard anti-ulcer drugs only partly protected.

Population

Review naming the Pliva development codes and reviewing the cytoprotection evidence, with a rat distended-stomach experiment

Intervention

BPC 157 instilled into the stomach

Comparator

Atropine, ranitidine, omeprazole

Limitations

Review by the originating group; the safety claim about the human trials cannot be checked against a published trial report.